<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Immune TTP: Treatment of clinical relapse</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Immune TTP: Treatment of clinical relapse</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Immune TTP: Treatment of clinical relapse</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James N George, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam Cuker, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H19005301"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy caused by severely reduced activity of the von Willebrand factor-cleaving protease ADAMTS13 (activity &lt;10 percent). It is characterized by small-vessel platelet-rich thrombi, thrombocytopenia, and microangiopathic hemolytic anemia (MAHA). Some patients may have neurologic abnormalities, mildly reduced kidney function, or low-grade fever. Immune TTP is caused by an autoantibody to ADAMTS13.</p><p>The use of therapeutic plasma exchange (TPE) and other therapies since the early 1990s has converted immune TTP from an almost uniformly fatal condition to a treatable disease. However, some patients with TTP will have refractory disease (transient, incomplete, or no response to treatment) and some will have one or more clinical relapses (additional episodes of TTP after initial recovery). </p><p>This topic reviews our approach to the patient with relapsed immune TTP or refractory disease. Refractory disease is becoming much less common due to the routine use of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> during initial therapy and in some patients <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a>. </p><p>Separate topics discuss:</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis – (See  <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">"Diagnosis of immune TTP"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Initial management – (See  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Management during remission, including ADAMTS13 monitoring and preemptive <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> – (See  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary TTP – (See  <a class="medical medical_review" href="/z/d/html/101504.html" rel="external">"Hereditary thrombotic thrombocytopenic purpura (hTTP)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced thrombotic microangiopathy – (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p></p><p class="headingAnchor" id="H19009592"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The following definitions are used to describe outcomes following therapy [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical remission</strong> – A sustained clinical response (normal platelet count, no new or progressive symptoms of TTP) for ≥30 days after therapeutic plasma exchange (TPE) or <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a> is stopped. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ADAMTS13 remission</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Partial – ADAMTS13 activity ≥20 percent but below the lower limit of normal for the assay.</p><p class="bulletIndent2"><span class="glyph">•</span>Complete – ADAMTS13 activity above the lower limit of normal for the assay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical relapse</strong> – Recurrence of an acute episode, manifested by thrombocytopenia and microangiopathic hemolytic anemia, in a patient who had a disease remission following an episode of TTP [<a href="#rid2">2,3</a>]. Asymptomatic decreases in ADAMTS13 activity do not constitute relapse, although they probably portend an increased risk for relapse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ADAMTS13 relapse</strong> – ADAMTS13 activity &lt;20 percent following an ADAMTS13 remission. Our approach to using preemptive <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> to reduce the risk of clinical relapse in individuals with an ADAMTS13 relapse is presented separately. (See  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Rituximab during remission to prevent relapse'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory TTP</strong> – Refractory TTP (lack of a clinical response to initial treatment, persistent thrombocytopenia, development of new or progressive organ ischemia due to TTP) is becoming very rare with the routine use of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> during initial therapy and in some cases <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a>. </p><p></p><p>Additional terminology is presented separately. (See  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Terminology and response criteria'</a>.)</p><p class="headingAnchor" id="H520413917"><span class="h1">REFRACTORY DISEASE</span></p><p class="headingAnchor" id="H2771887"><span class="h2">Overview of approach (refractory disease)</span><span class="headingEndMark"> — </span>Refractory TTP is becoming very rare; with the use of <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a> it may be eliminated. Our approach to the management is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of refractory disease should be evaluated thoroughly, so as not to miss another cause of worsening symptoms or laboratory findings  (<a class="graphic graphic_algorithm graphicRef120708" href="/z/d/graphic/120708.html" rel="external">algorithm 1</a>). A common occurrence is sepsis related to the central venous catheter. (See <a class="local">'Reevaluation of the diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If therapeutic plasma exchange (TPE) has been stopped, we restart it  (<a class="graphic graphic_algorithm graphicRef120707" href="/z/d/graphic/120707.html" rel="external">algorithm 2</a>). We do not increase the intensity or volume of plasma used [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment", section on 'Therapeutic plasma exchange'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We add <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a> in all individuals with refractory TTP. <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is also added if the patient is not already receiving rituximab, and we raise the dose of glucocorticoids. (See <a class="local">'Caplacizumab, glucocorticoids, and rituximab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals who cannot receive <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a>, or those who have persistent severe ADAMTS13 deficiency and are maintained in clinical remission with ongoing caplacizumab and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, additional immunosuppressive therapy is needed. Limited evidence from case reports provides information about other immunosuppressive therapies that may be helpful, with the choice among them individualized. Options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a> [<a href="#rid5">5-7</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a> [<a href="#rid8">8-12</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Cyclosporin [<a href="#rid13">13-16</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil [<a href="#rid17">17,18</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Splenectomy is also a consideration.</p><p></p><p>We do not use <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a> for immune TTP, although it does have a role in complement-mediated thrombotic microangiopathies. Consultation with a TTP expert is advised.</p><p class="headingAnchor" id="H19011564"><span class="h2">Reevaluation of the diagnosis</span><span class="headingEndMark"> — </span>Reevaluation of the diagnosis is essential in a patient whose disease does not respond to initial therapy or who has an exacerbation during or after stopping TPE. For some patients, a new diagnosis may be uncovered, such as a systemic infection, malignancy, or drug-induced thrombotic microangiopathy (DITMA). Even when the initial diagnosis of acquired TTP is correct, it may be possible for a patient to develop a new condition, such as an infection during or after effective therapy or drug-induced thrombocytopenia (DITP).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Infection may be present but unappreciated at the time of TTP diagnosis, or it may develop during therapy (eg, as a complication of an indwelling central venous catheter), with or without acute disseminated intravascular coagulation (DIC). Bacteremia related to the central venous catheter is common, and patients being treated with glucocorticoids may only have thrombocytopenia without fever [<a href="#rid19">19</a>]. Systemic infection mimicking TTP was illustrated in a review of 415 consecutive patients in the Oklahoma TTP-HUS Registry, in which clinical features were subsequently attributed to a systemic infection in 31 (7 percent) [<a href="#rid20">20</a>]. Additional reports have described occult infection or newly acquired infections in patients who appeared to have refractory or relapsed TTP [<a href="#rid21">21-25</a>]. In such cases, symptoms have responded to treatment of the infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy</strong> – Occult malignancy may produce an ongoing stimulus for microangiopathic hemolysis and thrombocytopenia, with or without chronic DIC. A thorough history and physical examination, as well as measurement of plasma fibrinogen and D-dimer and a bone marrow examination in selected patients, may be appropriate [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – The drug/medication history is important in patients with suspected refractory disease or relapse because symptoms may be related to a drug-induced thrombocytopenia (DITP) or drug-induced thrombotic microangiopathy (DITMA).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with TTP are often treated with antibiotics because of the initial suspicion of infection, and some antibiotics (eg, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>) are among the most common causes of DITP. (See  <a class="medical medical_review" href="/z/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">Quinine</a>  (<a class="graphic graphic_table graphicRef60296" href="/z/d/graphic/60296.html" rel="external">table 1</a>) is responsible for the majority of cases of DITMA, and many patients do not mention quinine use unless specifically asked about it. Questioning may reveal a previous temporal relationship with a specific drug that may not have been appreciated at the time. One dramatic example in our experience was a woman with recurrent acute episodes of thrombocytopenia, neutropenia, and fever during treatment for suspected TTP. Sepsis due to the central venous catheter was suspected repeatedly; only later did we learn that she had quinine-induced TMA and her husband was giving her quinine tablets in the hospital to relieve her leg cramps. (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p></p><p>We do not routinely remeasure ADAMTS13 activity to guide our assessment of ongoing symptoms or acute changes in disease status that may signify refractory disease, because the results of ADAMTS13 activity testing are not available immediately, and clinical assessment based on symptoms and platelet count are the most relevant information for decision making.</p><p>However, if facilities for prompt measurements are available, a repeat ADAMTS13 activity measurement may be helpful, particularly in patients with persistent or recurrent thrombocytopenia whose diagnosis is uncertain [<a href="#rid28">28-30</a>]. The continued presence of severe ADAMTS13 deficiency is consistent with continued activity of TTP as the cause of persistent or recurrent thrombocytopenia. Conversely, non-severely deficient ADAMTS13 activity (activity ≥10 percent) in a patient who has not received recent TPE is suggestive of an alternative process.</p><p>Monitoring of ADAMTS13 activity in remission, when there is not urgent time pressure to act on the results, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Detecting and preventing relapse'</a>.)</p><p class="headingAnchor" id="H3280506113"><span class="h2">Caplacizumab, glucocorticoids, and rituximab</span><span class="headingEndMark"> — </span>We add <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a> in all individuals with refractory TTP, if available. <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is also added if the patient is not already receiving rituximab, and we raise the dose of glucocorticoids. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">Caplacizumab</a> – Caplacizumab is a monoclonal antibody fragment that blocks the interaction between von Willebrand factor (VWF) and platelets; this is the interaction that mediate thrombosis in TTP. Rapid blocking of ongoing thrombosis is the most important intervention in refractory TTP, and caplacizumab is an essential intervention in these cases. Caplacizumab was approved in Europe in late 2018 and in the United States in early 2019. Some individuals may not have access to caplacizumab due to cost or lack of authorization in some countries.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dose</strong> – The dose of <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a> is 1 vial (10 mg in Europe; 11 mg in the United States; the actual amount is the same in the European and United States vials; only the labels differ). One dose is administered intravenously on day 1, followed by another dose subcutaneously and repeated once daily during TPE. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy</strong> – The package information states that <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a> should be continued during TPE and for 30 days after TPE has been stopped. Instead of using a fixed duration, we check ADAMTS13 activity weekly and stop caplacizumab when ADAMTS13 activity is ≥20 percent for two consecutive measurements  (<a class="graphic graphic_algorithm graphicRef120707" href="/z/d/graphic/120707.html" rel="external">algorithm 2</a>). In a minority of patients, ADAMTS13 recovery may not occur or may only recover after months or years despite optimization of immunosuppression. It is uncertain how long caplacizumab should be continued in such patients.  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rationale</strong> – Supporting evidence for <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a> in TTP is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment", section on 'Anti-VWF (caplacizumab)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-dose glucocorticoids</strong> – Glucocorticoids are routinely used in initial therapy, with high-dose glucocorticoids used for individuals with high-risk features. If an individual receiving lower-dose glucocorticoids has refractory disease, we raise the dose. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dose</strong> – We often use <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (eg, SoluMedrol) 1 gram intravenously daily for three days. This is followed by continued done for initial treatment (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg daily) followed by a rapid taper after PEX has been stopped and the platelet count has been normal for five to seven days after stopping PEX. (See  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment", section on 'Glucocorticoids'</a> and  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Monitoring and therapy after response to treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rationale</strong> – Evidence to support a specific dose of glucocorticoids is lacking; however, this regimen is standard treatment for patients who are critically ill with other autoimmune disorders such as lupus nephritis. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Glucocorticoid dosing and taper'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> – Rituximab has become routine initial treatment of most patients with immune TTP. If rituximab was not started initially and disease is refractory, we add rituximab. Exceptions may include an individual who is unable to tolerate rituximab or for whom there are concerns about rituximab use (eg, known hepatitis B infection), for whom a different immunosuppressive agent may be used. However, we do not delay rituximab to perform hepatitis B testing in a patient with refractory disease who is unstable or severely symptomatic. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dose</strong> – The optimal dose of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in refractory immune TTP has not been established, similar to in initial therapy. A dose of 375 mg/m<sup>2</sup> intravenously once a week for four consecutive weeks appears reasonable, based on extensive experience with this dose in other conditions [<a href="#rid28">28,31,32</a>]. However, lower doses or other schedules may be equally effective, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment", section on 'Rituximab'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> administration should be timed to occur immediately after the day's TPE rather than immediately beforehand, if possible, because TPE will deplete rituximab from the circulation. However, rituximab may be effective even if given on the same day prior to TPE; this may be because the dose of 375 mg/m<sup>2</sup> is in excess of the dose required to deplete autoantibody-producing B cells [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/3970.html" rel="external">"Overview of therapeutic monoclonal antibodies", section on 'Timing related to plasmapheresis or plasma exchange'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> therapy in combination with TPE has generally been well tolerated, with major complications not reported in the larger case series [<a href="#rid31">31,32,34</a>]. However, there are potential risks associated with rituximab, including infusion reactions, mucocutaneous reactions, prolonged immunosuppression, hepatitis B reactivation, and progressive multifocal leukoencephalopathy (PML), which is very rare. Our practice is not to place patients on antimicrobial prophylaxis, with the exception of patients with a history of hepatitis B virus infection, in whom antiviral therapy may be indicated. The decision regarding antiviral prophylaxis for hepatitis B is made in consultation with a hepatologist or infectious disease specialist. Prescribing information for rituximab contains Boxed Warnings about infusion reactions, hepatitis B reactivation, and PML. These toxicities are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a> and  <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rationale</strong> – Evidence demonstrating the efficacy of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in refractory immune TTP comes from case reports and observational studies [<a href="#rid5">5,32,34-45</a>]. Larger studies include the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One study compared outcomes of 21 patients with refractory TTP treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (375 mg/m<sup>2</sup> on days 1, 4, 7, and 14) with outcomes in 53 historical controls with refractory TTP who were treated with TPE with or without <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid34">34</a>]. Platelet count recovery was seen within 35 days in all patients treated with rituximab, compared with 41 of 53 controls (78 percent). The mean time to platelet count normalization was 12±6.7 days with rituximab. There was a nonsignificant trend towards decreased relapse at one year, and no difference in relapse after one year.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Another study that included 25 patients with refractory and/or relapsed TTP reported remission in all patients at a median of 11 days after initiating <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (375 mg/m<sup>2</sup> once per week for at least four doses) [<a href="#rid32">32</a>]. Treatment beyond four doses, to a maximum of eight, was given to four patients who continued to have reduced ADAMTS13 activity or persistent anti-ADAMTS13 antibodies. There were no relapses at a median follow-up of 10 months.</p><p></p><p class="bulletIndent2">Evidence for <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in the first line setting (as initial therapy) also supports its addition for refractory disease. (See  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment", section on 'Rituximab'</a>.)</p><p></p><p class="headingAnchor" id="H395902"><span class="h1">CLINICAL RELAPSE</span><span class="headingEndMark"> — </span>The following discussion of relapse refers to clinical relapse, with thrombocytopenia and microangiopathic hemolytic anemia. Sometimes patients also have symptoms or findings of organ dysfunction. (See <a class="local">'Terminology'</a> above.) </p><p>Monitoring asymptomatic individuals for ADAMTS13 relapse (see <a class="local">'Terminology'</a> above) and preemptive <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> to reduce the risk of clinical relapse is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Detecting and preventing relapse'</a>.)</p><p class="headingAnchor" id="H328727"><span class="h2">Risk of clinical relapse</span><span class="headingEndMark"> — </span>Most patients will not have a relapse of TTP, especially in the era of routine initial <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and use of <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a> in some individuals. </p><p>In our experience (JNG) prior to the routine use of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, relapse occurred in 23 of 67 patients (34 percent) who survived an acute episode of TTP [<a href="#rid36">36</a>]. However, the rate of relapse has been decreasing over time. In the decade from 2005 to 2014, only 6 of 34 patients (18 percent) have experienced a relapse, compared with 17 of 33 patients (52 percent) in the prior decade (1995 to 2004). Among patients treated with rituximab during their initial episode, only two (6 percent) of 16 patients have relapsed with a median follow-up of three years, which is significantly less than the frequency of relapse among patients who had not been treated with rituximab (9 of 21 [43 percent]) [<a href="#rid46">46</a>]. </p><p>The main risk factor for relapse is persistent severe ADAMTS13 deficiency or ADAMTS13 relapse (activity &lt;20 percent) during remission. (See  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Natural history of ADAMTS13 activity during remission'</a>.)</p><p>Patients who experience a relapse may have multiple subsequent relapses; however, half of our relapsed patients have had only a single relapse. This may be due in part to our use of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> for treatment of relapse episodes.</p><p>When relapses occur, they are most likely to do so in the first year following recovery (approximately half of relapses). Among all 23 patients who have relapsed, the timing of relapses was as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>First year – 11 patients (48 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Years 1 to 3 – 7 patients (30 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Years 5 to 14 – 5 patients (22 percent)</p><p></p><p>Relapses have also been observed at much longer intervals (up to 16 years in our experience). Thus, monitoring is most critical during the first year but remains important indefinitely. (See  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Monitoring and therapy after response to treatment'</a>.)</p><p class="headingAnchor" id="H448440267"><span class="h2">Symptoms of clinical relapse</span><span class="headingEndMark"> — </span>Relapse episodes of TTP are typically less severe than initial episodes, presumably because patients are aware of the symptoms and promptly contact their hematologist who managed their initial episode. A comparison of initial episodes with the first relapse in 23 patients demonstrated fewer presentations with coma, seizure, and/or stroke but similar frequencies of transient focal neurologic abnormalities in relapse episodes [<a href="#rid47">47</a>]. Transient focal abnormalities were immediately recognized by the patients as indicating relapse, and they immediately contacted their hematologist. With relapse episodes, platelet counts and hematocrits were significantly higher and lactate dehydrogenase (LDH) levels were significantly lower than with the initial episodes.</p><p>It is especially important not to attribute minor symptoms to unrelated illnesses. Symptoms that are best treated with a "watch and wait" approach in patients without a history of TTP <strong>cannot</strong> be treated the same way in a patient with a history of TTP. A patient with a history of TTP who exhibits these or any other symptoms of illness requires an immediate (same-day) evaluation of the complete blood count (CBC) with platelet count and immediate intervention if thrombocytopenia is found. (See <a class="local">'Clinical relapse'</a> above and  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Monitoring and therapy after response to treatment'</a>.)</p><p class="headingAnchor" id="H375592248"><span class="h2">Diagnostic evaluation for clinical relapse</span><span class="headingEndMark"> — </span>The most important laboratory finding in TTP relapse is thrombocytopenia (platelet count &lt;150,000/microL). Thrombocytopenia strongly suggests disease relapse, although other explanations (infection, drug-induced) are possible. For any symptoms that may suggest a relapse, it is critical that a CBC with platelet count be obtained and reviewed on the same day. This may be facilitated by the patient carrying a wallet card to present to emergency department personnel or other clinicians who are unfamiliar with the patient's history or with TTP  (<a class="graphic graphic_form graphicRef116336" href="/z/d/graphic/116336.html" rel="external">form 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>For any symptomatic patient with a platelet count &lt;100,000/microL, urgent additional diagnostic evaluations are essential, including review of the peripheral blood smear for schistocytes and measurement of LDH and haptoglobin to assess hemolysis. If these initial observations are consistent with TTP, immediate initiation of therapeutic plasma exchange (TPE) is necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If an asymptomatic patient is discovered to have a platelet count between 100,000 and 150,000/microL on a routine CBC, management is individualized. Some patients for whom this represents a major decrease in platelet count may require urgent evaluation for a TTP relapse and initiation of TPE, whereas for others it may be appropriate to monitor the platelet count daily to determine the etiology.</p><p></p><p>Any patient with suspected relapse due to worrisome symptoms and/or thrombocytopenia requires urgent (same-day) evaluation. If thrombocytopenia has already been documented, the evaluation should occur in the hospital with the understanding that urgent TPE may be required. We do the following:</p><p class="bulletIndent1"><span class="glyph">●</span>CBC with platelet count, if not already done</p><p class="bulletIndent1"><span class="glyph">●</span>Review of the peripheral blood smear for schistocytes</p><p class="bulletIndent1"><span class="glyph">●</span>Testing for hemolysis, including total bilirubin, LDH, and haptoglobin</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine, to evaluate any worsening of kidney function</p><p class="bulletIndent1"><span class="glyph">●</span>ADAMTS13 activity level</p><p></p><p>The ADAMTS13 activity level may not be available for several days, and management decisions should not be delayed while awaiting the results.</p><p>Diagnosis of TTP relapse is the same as the initial episode (eg, thrombocytopenia [platelet count &lt;150,000/microL] and microangiopathic hemolytic anemia, with or without neurologic findings or reduced kidney function, without another apparent cause). (See  <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">"Diagnosis of immune TTP", section on 'Evaluation and diagnosis'</a>.)</p><p class="headingAnchor" id="H328733"><span class="h2">Management of clinical relapse</span><span class="headingEndMark"> — </span>Once a diagnosis of TTP relapse is made, urgent TPE, glucocorticoids, and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> are appropriate. Details of acute therapy are similar to the initial episode and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment"</a>.)</p><p>For selected individuals, we would include <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a>. Examples are similar to those that would prompt us to use caplacizumab in the initial presentation and include those whose relapse presented with severe disease (neurologic findings and/or elevated troponin levels) and those whose relapse was refractory to TPE, glucocorticoids, and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. (See  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment", section on 'Anti-VWF (caplacizumab)'</a>.)</p><p>For selected individuals, we may omit <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. An example would be an individual who had a prior good response to TPE and glucocorticoids alone (ie, without rituximab) and who places a higher value on avoiding prolonged immunosuppression; for such an individual, rituximab may reasonably be omitted. Other potential reasons to omit rituximab include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient just completed a course of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a></p><p class="bulletIndent1"><span class="glyph">●</span>The patient previously did not have a response to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (eg, ADAMTS13 activity did not increase)</p><p class="bulletIndent1"><span class="glyph">●</span>The patient is in the second or third trimester of pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>The patient has another condition or is receiving other medications that cause profound immunosuppression</p><p class="bulletIndent1"><span class="glyph">●</span>The patient has a history of hepatitis B infection</p><p></p><p>The management of a relapse assumes the correct initial diagnosis of immune TTP and determination that the thrombocytopenia and recurrent symptoms, if present, are not due to an alternative diagnosis Checking ADAMTS13 activity in patients with suspected relapse is important to confirm the diagnosis of relapsed TTP, but, as with initial treatment, therapy should not be delayed while awaiting the results of this testing. (See <a class="local">'Reevaluation of the diagnosis'</a> above.)</p><p class="headingAnchor" id="H3238420677"><span class="h2">Multiple relapses</span><span class="headingEndMark"> — </span>For individuals with multiple relapses, the following options may be appropriate in addition to treating the acute event:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> – Maintenance rituximab is sometimes used, such as a single dose of 375 mg/m<sup>2</sup> once every three months for two to three years. (See  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Rituximab during remission to prevent relapse'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splenectomy </strong>– Several reports have described the use of splenectomy [<a href="#rid48">48-51</a>]. All of these describe success in preventing or decreasing the frequency of subsequent relapses. The rationale for this is the identification of ADAMTS13-specific memory B cells in the spleens of two patients with acquired TTP who underwent splenectomy [<a href="#rid52">52</a>]. Cultured cells from both spleens produced anti-ADAMTS13 IgG antibodies that shared common complementarity-determining regions (CDRs). These findings were interpreted as suggesting that splenic B cells have a limited repertoire against ADAMTS13 and that these cells are critical in producing the ADAMTS13 inhibitor in acquired TTP. Following splenectomy, both patients have been free of relapse with normal ADAMTS13 activity for 8 and 11 years.</p><p></p><p class="bulletIndent1">Splenectomy carries risks of infections, especially with encapsulated organisms, as well as thrombosis and perioperative risks. Surgical expertise is critical, and laparoscopic procedures appear to be associated with lower risks of adverse events. Patients should be educated regarding these risks and their mitigation, and appropriate immunizations should be provided before the procedure, as discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function"</a> and  <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">"Elective (diagnostic or therapeutic) splenectomy", section on 'Postoperative risks'</a>.)</p><p></p><p class="headingAnchor" id="H4074447769"><span class="h2">Prognosis after relapse</span><span class="headingEndMark"> — </span>The mortality of relapsed TTP is less than with the initial episode [<a href="#rid53">53,54</a>]. Potential reasons for this include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients whose disease relapses have by definition had a disease remission in response to initial therapy, so it is likely that their disease will respond to therapy again.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have had a previous episode of TTP are familiar with the presenting symptoms and therefore do not delay in contacting their clinician.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is less (or no) uncertainty about making the diagnosis and initiating therapy.</p><p></p><p>However, individuals with TTP are at risk for long-term complications including heart disease, kidney disease, hypertension, cognitive decline, and depression. Thus, they require lifelong monitoring for these complications and appropriate treatment as indicated. (See  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Evaluation for complications of TTP'</a>.)</p><p>Management of pregnancy in a patient who previous had TTP is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment", section on 'Immune TTP during pregnancy'</a>.)</p><p class="headingAnchor" id="H1041556564"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117846.html" rel="external">"Society guideline links: Thrombotic microangiopathies (TTP, HUS, and related disorders)"</a>.)</p><p class="headingAnchor" id="H470712933"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/140049.html" rel="external">"Patient perspective: Thrombotic thrombocytopenic purpura (TTP)"</a>.)</p><p class="headingAnchor" id="H19005308"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Terminology for thrombotic thrombocytopenic purpura (TTP) syndromes and outcomes of therapy are summarized above ADAMTS13 relapse (activity &lt;20 percent without thrombocytopenia or symptoms of TTP) is treated differently from clinical relapse. (See <a class="local">'Terminology'</a> above and  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Detecting and preventing relapse'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory disease</strong> – Refractory disease is the lack of a clinical response to initial treatment with therapeutic plasma exchange (TPE), glucocorticoids, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and in some cases <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a>; this is becoming increasingly rare in the era of routine rituximab and caplacizumab. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation</strong> – The diagnosis of refractory disease should be evaluated thoroughly, so as not to miss another cause of worsening symptoms or laboratory findings. A common occurrence is sepsis related to the central venous catheter. (See <a class="local">'Reevaluation of the diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management –</strong> Our approach is as follows (see <a class="local">'Overview of approach (refractory disease)'</a> above and <a class="local">'Caplacizumab, glucocorticoids, and rituximab'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If TPE has been discontinued, daily TPE should be reinitiated  (<a class="graphic graphic_algorithm graphicRef120708" href="/z/d/graphic/120708.html" rel="external">algorithm 1</a>). For patients with refractory TTP despite ongoing daily TPE, we suggest not increasing the frequency or intensity of TPE (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who are not receiving <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">caplacizumab</a> (those who never received it or those who received it and then discontinued it), we suggest caplacizumab (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We continue therapy until ADAMTS13 activity is ≥20 percent on two measurements. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest an intensified glucocorticoid regimen, using <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (eg, SoluMedrol) 1 gram intravenously, daily for three days (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For individuals who have not yet received <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> for treatment of this episode of TTP, we recommend adding rituximab (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical relapse</strong> – Clinical relapse is recurrence of thrombocytopenia and microangiopathic hemolytic anemia without another cause following remission, which is later confirmed by documenting severe ADAMTS13 deficiency (activity &lt;10 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation</strong> – It is especially important not to attribute minor symptoms to unrelated illnesses. Symptoms that are best treated with a "watch and wait" approach in patients without a history of TTP <strong>cannot</strong> be treated the same way in a patient with a history of TTP. A patient with a history of TTP who exhibits these or any other symptoms of illness requires an immediate (same-day) evaluation of the complete blood count (CBC) with platelet count and immediate intervention if thrombocytopenia is found. (See <a class="local">'Symptoms of clinical relapse'</a> above and <a class="local">'Diagnostic evaluation for clinical relapse'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – A clinical relapse should be treated promptly with daily TPE and glucocorticoids, done for the initial episode (see  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment"</a>). For all patients with a first TTP relapse, we suggest adding <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, regardless of whether rituximab was administered with the initial episode (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">Caplacizumab</a> is reserved for selected individuals with high-risk features (neurologic findings and/or elevated troponin levels). Maintenance rituximab or splenectomy may also be an option, especially for those with multiple relapses. (See <a class="local">'Clinical relapse'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention</strong> – Patients are monitored closely during tapering of therapy and after recovery. <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is used in most cases of ADAMTS13 relapse to reduce the risk of clinical relapse  (<a class="graphic graphic_algorithm graphicRef120707" href="/z/d/graphic/120707.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">"Immune TTP: Management following recovery from an acute episode and during remission", section on 'Detecting and preventing relapse'</a>.)</p><p></p><p class="headingAnchor" id="H231514290"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate acknowledges Andre A Kaplan, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cuker A, Cataland SR, Coppo P, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood 2021; 137:1855.</a></li><li><a class="nounderline abstract_t">Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood 2015; 125:1526.</a></li><li><a class="nounderline abstract_t">Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102:60.</a></li><li><a class="nounderline abstract_t">Nguyen L, Li X, Duvall D, et al. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 2008; 48:349.</a></li><li><a class="nounderline abstract_t">Zheng X, Pallera AM, Goodnough LT, et al. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138:105.</a></li><li><a class="nounderline abstract_t">Beloncle F, Buffet M, Coindre JP, et al. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 2012; 52:2436.</a></li><li><a class="nounderline abstract_t">Stein GY, Zeidman A, Fradin Z, et al. Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol 2004; 80:94.</a></li><li><a class="nounderline abstract_t">van Balen T, Schreuder MF, de Jong H, van de Kar NC. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol 2014; 92:80.</a></li><li><a class="nounderline abstract_t">Yates S, Matevosyan K, Rutherford C, et al. Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion 2014; 54:2064.</a></li><li><a class="nounderline abstract_t">Mazepa MA, Raval JS, Moll S, et al. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2014; 164:900.</a></li><li><a class="nounderline abstract_t">Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013; 368:90.</a></li><li><a class="nounderline abstract_t">Patel PP, Becker J, Freyer C, et al. Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib. Transfusion 2016; 56:970.</a></li><li><a class="nounderline abstract_t">Cataland SR, Jin M, Zheng XL, et al. An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4:1162.</a></li><li><a class="nounderline abstract_t">Cataland SR, Jin M, Lin S, et al. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 2007; 139:486.</a></li><li><a class="nounderline abstract_t">Cataland SR, Jin M, Ferketich AK, et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007; 136:146.</a></li><li><a class="nounderline abstract_t">Bachman WR, Brennan JK. Refractory thrombotic thrombocytopenic purpura treated with cyclosporine. Am J Hematol 1996; 51:93.</a></li><li><a class="nounderline abstract_t">Ahmad HN, Thomas-Dewing RR, Hunt BJ. Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura. Eur J Haematol 2007; 78:449.</a></li><li><a class="nounderline abstract_t">Beeker-Koepke SJ, Kudva GC, Grossman BJ. A case of relapsing, refractory thrombotic thrombocytopenic purpura responsive to mycophenolate mofetil. J Clin Apher 2008; 23:39.</a></li><li><a class="nounderline abstract_t">McClain RS, Terrell DR, Vesely SK, George JN. Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011 to 2014. Transfusion 2014; 54:3257.</a></li><li><a class="nounderline abstract_t">Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol 2011; 86:743.</a></li><li><a class="nounderline abstract_t">Kanj NA, Mikati AR, Kfoury Baz EM. Early relapse of thrombotic thrombocytopenic purpura during therapeutic plasma exchange associated with Acinetobacter anitratus bacteremia. Ther Apher Dial 2003; 7:119.</a></li><li><a class="nounderline abstract_t">Creager AJ, Brecher ME, Bandarenko N. Thrombotic thrombocytopenic purpura that is refractory to therapeutic plasma exchange in two patients with occult infection. Transfusion 1998; 38:419.</a></li><li><a class="nounderline abstract_t">Niv E, Segev A, Ellis MH. Staphylococcus aureus bacteremia as a cause of early relapse of thrombotic thrombocytopenic purpura. Transfusion 2000; 40:1067.</a></li><li><a class="nounderline abstract_t">Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura? J Clin Apher 2007; 22:21.</a></li><li><a class="nounderline abstract_t">Douglas KW, Pollock KG, Young D, et al. Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience. J Clin Apher 2010; 25:47.</a></li><li><a class="nounderline abstract_t">Parekh HD, Reese JA, Cobb PW, George JN. Bone marrow necrosis discovered in a patient with suspected thrombotic thrombocytopenic purpura. Am J Hematol 2015; 90:264.</a></li><li><a class="nounderline abstract_t">George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park) 2011; 25:908.</a></li><li><a class="nounderline abstract_t">Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood 2015; 125:3860.</a></li><li><a class="nounderline abstract_t">Wu N, Liu J, Yang S, et al. Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion 2015; 55:18.</a></li><li><a class="nounderline abstract_t">van der Veen BS, Besseling R, Hoogendoorn M. Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura. Transfusion 2015; 55:2511.</a></li><li><a class="nounderline abstract_t">Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118:1746.</a></li><li><a class="nounderline abstract_t">Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136:451.</a></li><li><a class="nounderline abstract_t">McDonald V, Manns K, Mackie IJ, et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8:1201.</a></li><li><a class="nounderline abstract_t">Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40:104.</a></li><li><a class="nounderline abstract_t">George JN. Controlling chronic TTP (editorial). Blood 2005; 106:1896.</a></li><li><a class="nounderline abstract_t">Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115:1500.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106:1932.</a></li><li><a class="nounderline abstract_t">Yomtovian R, Niklinski W, Silver B, et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124:787.</a></li><li><a class="nounderline abstract_t">Ahmad A, Aggarwal A, Sharma D, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004; 77:171.</a></li><li><a class="nounderline abstract_t">Galbusera M, Bresin E, Noris M, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005; 106:925.</a></li><li><a class="nounderline abstract_t">Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008; 141:149.</a></li><li><a class="nounderline abstract_t">Jasti S, Coyle T, Gentile T, et al. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 2008; 23:151.</a></li><li><a class="nounderline abstract_t">Bhagirath VC, Kelton JG, Moore J, Arnold DM. Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura. Transfusion 2012; 52:2517.</a></li><li><a class="nounderline abstract_t">Chemnitz JM, Uener J, Hallek M, Scheid C. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 2010; 89:1029.</a></li><li><a class="nounderline abstract_t">de la Rubia J, Moscardó F, Gómez MJ, et al. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci 2010; 43:299.</a></li><li><a class="nounderline abstract_t">Page EE, Kremer Hovinga JA, Terrell DR, et al. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood 2016; 127:3092.</a></li><li><a class="nounderline abstract_t">Page EE, Kremer Hovinga JA, Terrell DR, et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 2017; 1:590.</a></li><li><a class="nounderline abstract_t">Aqui NA, Stein SH, Konkle BA, et al. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apher 2003; 18:51.</a></li><li><a class="nounderline abstract_t">Kappers-Klunne MC, Wijermans P, Fijnheer R, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005; 130:768.</a></li><li><a class="nounderline abstract_t">Kremer Hovinga JA, Studt JD, Demarmels Biasiutti F, et al. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica 2004; 89:320.</a></li><li><a class="nounderline abstract_t">Crowther MA, Heddle N, Hayward CP, et al. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med 1996; 125:294.</a></li><li><a class="nounderline abstract_t">Schaller M, Vogel M, Kentouche K, et al. The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. Blood 2014; 124:3469.</a></li><li><a class="nounderline abstract_t">Forzley BR, Sontrop JM, Macnab JJ, et al. Treating TTP/HUS with plasma exchange: a single centre's 25-year experience. Br J Haematol 2008; 143:100.</a></li><li><a class="nounderline abstract_t">Lotta LA, Mariani M, Consonni D, et al. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 2010; 151:488.</a></li></ol></div><div id="topicVersionRevision">Topic 99124 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33529333" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Redefining outcomes in immune TTP: an international working group consensus report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25573992" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637323" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18028271" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529092" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22404639" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15293577" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24118335" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24655327" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24345005" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23281998" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26779871" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16689782" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17910638" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17069579" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8571946" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Refractory thrombotic thrombocytopenic purpura treated with cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17331134" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A case of relapsing, refractory thrombotic thrombocytopenic purpura responsive to mycophenolate mofetil</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25496391" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011 to 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21850657" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Systemic infections mimicking thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12921127" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Early relapse of thrombotic thrombocytopenic purpura during therapeutic plasma exchange associated with Acinetobacter anitratus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9633552" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Thrombotic thrombocytopenic purpura that is refractory to therapeutic plasma exchange in two patients with occult infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10988308" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Staphylococcus aureus bacteremia as a cause of early relapse of thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17285617" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20101677" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25196665" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bone marrow necrosis discovered in a patient with suspected thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010388" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25784681" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : How I treat refractory thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24953079" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26308736" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21636861" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17233847" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20175870" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21926591" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Controlling chronic TTP (editorial)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20032506" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Survival and relapse in patients with thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15933059" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009067" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389904" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827129" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18318765" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Rituximab in the treatment of autoimmune haematological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18712712" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22486316" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20422413" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20934383" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27060171" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296701" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12874815" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16115135" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Splenectomy for the treatment of thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15020271" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8678392" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25261198" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18691172" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treating TTP/HUS with plasma exchange: a single centre's 25-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955397" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
